Quantum BioPharma is trading at $3.57, down 6.65%, with no clear company-specific catalyst for the September 30, 2026 decline found in available coverage. - A September 30 podcast announcement featuring the company’s executive co-chair was reported, but coverage did not connect it to the share-price move. - Recent FDA Lucid-MS Phase 2 news and other company announcements predate the session; supplied major-index moves were mixed and below the stated threshold for a broad-market explanation.